高剂量左氧氟沙星序贯法治疗呼吸道感染的安全性与有效性研究

目的评价高剂量左氧氟沙星先静脉后口服序贯给药治疗呼吸道感染的疗效与安全性。方法采用前瞻性开放试验设计方法,对60例急性呼吸道感染患者,采用高剂量左氧氟沙星（可乐必妥）500 mg静脉滴注,1次/d,3-5 d,继以可乐必妥500 mg口服,1次/d,5-10 d,总疗程8-15 d。观察临床疗效和不良反应情况。结果临床总有效率为95.0%。其中临床症状和体征改善有效率为100%,胸片阴影改善好转率为90%,降低白细胞计数及中性粒细胞有效率为100%,细菌清除率100%。不良反应以胃肠道反应为多见,实验室检查异常均系轻度改变,并呈一过性,无需处理。结论高剂量左氧氟沙星500 mg静脉口服序贯法给药,用于治疗呼吸道感染可获良好疗效,使用安全,不良反应发生率低,且经济方便,患者依从性好。

Clinical efficacy and safety research of a high-dose levofloxacin sequential therapy in the treatment of the patients with respiratory infections

Objective To evaluate the clinical therapeutic effect and safety of sequential intravenous-to-oral （IV/PO） high dose （500 mg） levofloxacin therapy for the treatment of patients with respiratory infections. Methods A prospective, randomized, open clinical trial by using high dose （500 mg） levofloxacin （cravit） by intravenous infusion once-daily for 3 - 5 days, followed by oral levofloxacin 500 mg once-daily for 5 - 10 days was conducted in 60 volunteers with acute respiratory infections. The duration was 8 - 15 days. The clinical curative effect and the adverse reactions were analyzed after the completion of the treatment. Results The clinical total effective rate was 95.0%, and the rate of clinical symptom and sign improvement was 100%. The chest x-ray shadow improvement rate was 90%, reduced white blood cell count and neutral granular cells rate 100%, and bacteria clearance rate 100%. The incidence of treatment-related adverse events was low, and the main adverse drug reactions were the gastro-intestinal tract responses and mild abnormal laboratory parameter changes with short duration, no need for treatment. Conclusion The study shows that the sequential IV/PO high dose levofloxacin therapy in the treatment of respiratory infections enjoy the advantages such as greater clinical efficacy, safety, less adverse drug reactions, lower cost, convenience, and improved patient compliance